Related Experiment Video

Updated: Aug 6, 2026

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
06:21

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

E2F1 as a target: promoter-driven suicide and small molecule modulators

William G Kaelin1

  • 1Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA. william_kaelin@dfci.harvard.edu

Cancer Biology & Therapy
|September 26, 2003
PubMed

Insights

Cancer cells evade growth controls and anti-growth signals due to mutations affecting the retinoblastoma protein (pRB). This impacts E2F transcription factors, driving cell proliferation and potentially apoptosis, offering cancer treatment targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Cycle Regulation

Background:

  • Human cancers exhibit reduced dependency on growth factors (mitogens) and decreased sensitivity to growth-inhibiting signals.
  • These cancer hallmarks are often linked to compromised function of the retinoblastoma tumor suppressor protein (pRB).
  • pRB acts as a negative regulator of E2 transcription factors (E2Fs), which control cell cycle progression.

Purpose of the Study:

  • To review the critical role of E2F transcription factors in the development of human cancers.
  • To explore the potential of targeting E2F biology for novel anticancer therapeutic strategies.

Main Methods:

  • Review of existing scientific literature on pRB, E2F, cell cycle regulation, and cancer biology.
  • Analysis of the mechanisms by which E2F activation contributes to both proliferation and apoptosis in cancer.

Main Results:

  • Mutations compromising pRB function lead to dysregulated E2F activity.
  • Activated E2F drives unscheduled cell proliferation, a key feature of cancer.
  • E2F activation can also trigger programmed cell death (apoptosis) under specific conditions.

Conclusions:

  • The retinoblastoma protein (pRB) and E2F transcription factors are central players in cell cycle control and cancer development.
  • Understanding the intricate E2F pathway offers significant opportunities for developing targeted anticancer therapies.

More Related Videos

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing10:44

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing

Published on: May 5, 2023

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...